Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 7:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 94 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cirrhosis, Biliary Clear all
Completed Phase 1Phase 2 Interventional Results available

Initial Study of Rituximab to Treat Primary Biliary Cirrhosis

NCT00364819
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
rituximab
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 4, 2026, 7:34 AM EDT
Completed Phase 3 Interventional

Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary Cirrhosis

NCT00805805
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Tetrathiomolybdate, Placebo
Drug · Other
Lead sponsor
George Brewer
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 4, 2026, 7:34 AM EDT
Completed Phase 1 Interventional

Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis (PBC)

NCT00943176
View directory record Official record
Conditions
Fatigue, Primary Biliary Cirrhosis
Interventions
Modafinil
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 18, 2012 · Synced Oct 4, 2026, 7:34 AM EDT
Completed Phase 2 Interventional Results available

Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)

NCT02955602
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
MBX-8025 2 mg Capsule, MBX-8025 5 mg Capsule, MBX-8025 10 mg Capsule
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
23
States / cities
Chandler, Arizona • Coronado, California • Palo Alto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 4, 2026, 7:34 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis

NCT03394924
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
EDP-305 1 mg, EDP-305 2.5 mg, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
40
States / cities
Dothan, Alabama • Little Rock, Arkansas • Coronado, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 4, 2026, 7:34 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Sulfation of Bile Acids as a Biomarker for Hepatobiliary Diseases

NCT01200082
View directory record Official record
Conditions
Hepatobiliary Diseases
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 65 Years
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 4, 2026, 7:34 AM EDT
Completed Phase 2 Interventional

Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis

NCT02135536
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
NGM282
Biological
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Phoenix, Arizona • Coronado, California • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 4, 2026, 7:34 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid

NCT03124108
View directory record Official record
Conditions
Primary Biliary Cholangitis (PBC)
Interventions
Elafibranor 80 mg, Elafibranor 120 mg, Placebo
Drug
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
13
States / cities
Phoenix, Arizona • Miami, Florida • Weston, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 4, 2026, 7:34 AM EDT
Recruiting Phase 1 Interventional

Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease

NCT06825559
View directory record Official record
Conditions
Cholestatic Liver Disease
Interventions
Saroglitazar Magnesium 1 mg
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 4, 2026, 7:34 AM EDT
Terminated No phase listed Observational

TruGraf Liver Gene Expression Serial Test

NCT06061341
View directory record Official record
Conditions
Autoimmune Liver Disease, Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis
Interventions
TruGraf®
Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 4, 2026, 7:34 AM EDT
Completed Phase 3 Interventional

Ursodiol-Methotrexate for Primary Biliary Cirrhosis

NCT00006168
View directory record Official record
Conditions
Liver Cirrhosis, Biliary
Interventions
Methotrexate
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
20 Years to 69 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2004
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2010 · Synced Oct 4, 2026, 7:34 AM EDT
Completed Phase 3 Interventional

Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)

NCT06060665
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Seladelpar 10 mg, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
43
States / cities
Chandler, Arizona • Pasadena, California • Sacramento, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 4, 2026, 7:34 AM EDT
Completed No phase listed Observational

Genetic Epidemiology of Primary Biliary Cirrhosis (PBC)

NCT01161953
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Genetic Analysis
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 4, 2026, 7:34 AM EDT
Completed Phase 2 Interventional

Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis

NCT02026401
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
NGM282, Placebo
Biological
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
7
States / cities
Phoenix, Arizona • Coronado, California • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 4, 2026, 7:34 AM EDT
Recruiting Phase 1 Interventional

A Study of SIPLIZUMAB in AILD and LT Patients

NCT06455280
View directory record Official record
Conditions
Autoimmune Liver Disease, Liver Transplant Disorder, Autoimmune Hepatitis, Primary Sclerosing Cholangitis, End Stage Liver DIsease, Cirrhosis, Liver
Interventions
Siplizumab
Drug
Lead sponsor
Elizabeth C. Verna
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 4, 2026, 7:34 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis

NCT01904058
View directory record Official record
Conditions
PBC, Primary Biliary Cirrhosis
Interventions
LUM001, Placebo, Ursodeoxycholic Acid
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
17
States / cities
La Jolla, California • Sacramento, California • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 4, 2026, 7:34 AM EDT
Terminated Not applicable Interventional Results available

BRIDGE Device for Post-operative Pain Control

NCT03265249
View directory record Official record
Conditions
Liver Failure, Liver Diseases, Alcoholic, Liver Diseases, Pain, Postoperative, Transplant; Failure, Liver, Liver Cirrhosis, Biliary
Interventions
BRIDGE device
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 4, 2026, 7:34 AM EDT
Completed Phase 2 Interventional Results available

A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid

NCT01389973
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
ustekinumab 90 mg, ustekinumab 45 mg, ustekinumab 180 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Jacksonville, Florida • Miami, Florida • Naples, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2016 · Synced Oct 4, 2026, 7:34 AM EDT
Completed No phase listed Observational

A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria)

NCT07049887
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Not listed
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Chandler, Arizona • Miami, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 4, 2026, 7:34 AM EDT
Terminated Phase 2 Interventional

SAMe to Treat Biliary Cirrhosis Symptoms

NCT00125281
View directory record Official record
Conditions
Liver Cirrhosis, Biliary
Interventions
S-adenosyl-methionine (SAMe) capsules
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 4, 2026, 7:34 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA

NCT03742973
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
10
States / cities
Coronado, California • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 4, 2026, 7:34 AM EDT
Completed Phase 3 Interventional

A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

NCT06383403
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Elafibranor, Placebo
Drug · Other
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
20
States / cities
Coronado, California • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 4, 2026, 7:34 AM EDT
Recruiting Phase 3 Interventional

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

NCT06051617
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Seladelpar, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Lancaster, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 4, 2026, 7:34 AM EDT
Completed Phase 2 Interventional Results available

Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis

NCT04604652
View directory record Official record
Conditions
Primary Biliary Cholangitis, Primary Biliary Cirrhosis, Cholangitis, Cholestasis, Biliary Tract Diseases, Bile Duct Stricture
Interventions
HTD1801 (BUDCA)
Drug
Lead sponsor
HighTide Therapeutics (Hong Kong) Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
12
States / cities
Miami, Florida • Atlanta, Georgia • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 4, 2026, 7:34 AM EDT